Tepmetko (Tepotinib HCl) Patent Expiration, LOE Window & CMS Spending
Tepmetko (Tepotinib HCl) by Emd Serono: FDA Orange Book core substance LOE 2030-03-19, 0 AB generics, $42.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Emd Serono |
| FDA Application & Pathway | N214096 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2030-03-19 |
| Last Listed Patent or Exclusivity Date | 2030-03-19 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $42.1M |
| 2024 Medicare Part D Spend | $40.6M |
| 2024 Medicaid Spend | $1.6M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 17.4% 2-yr change) |